VYNE Therapeutics (NASDAQ:VYNE) Coverage Initiated by Analysts at BTIG Research

BTIG Research started coverage on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research note issued to investors on Monday,Briefing.com Automated Import reports. The brokerage set a “buy” rating and a $8.00 price target on the stock. BTIG Research’s price target indicates a potential upside of 196.30% from the stock’s current price.

Separately, HC Wainwright restated a “buy” rating and set a $5.75 price target on shares of VYNE Therapeutics in a report on Friday, November 8th.

VYNE Therapeutics Stock Performance

Shares of VYNE stock opened at $2.70 on Monday. VYNE Therapeutics has a 52-week low of $1.57 and a 52-week high of $4.30. The stock has a fifty day simple moving average of $2.27 and a two-hundred day simple moving average of $2.18. The firm has a market capitalization of $39.83 million, a PE ratio of -3.14 and a beta of 1.32.

Hedge Funds Weigh In On VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP acquired a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics makes up about 0.0% of Lynx1 Capital Management LP’s investment portfolio, making the stock its 17th biggest position. Lynx1 Capital Management LP owned about 0.11% of VYNE Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.